MicroRNA classifier and nomogramfor metastasis prediction in colon cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 187-197

  Goossens Beumer, Inès J ^a   Derr, Remco S ^a   Buermans, Henk P J ^a   Goeman, Jelle J ^b   Böhringer, Stefan ^a   Morreau, Hans ^a   Nitsche, Ulrich ^c   Janssen, Klaus Peter ^c   Van De Velde, Cornelis J H ^a   Kuppen, Peter J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 106B; MICRORNA 1226; MICRORNA 135A; MICRORNA 140; MICRORNA 147B; MICRORNA 16; MICRORNA 188; MICRORNA 200C; MICRORNA 205; MICRORNA 25; MICRORNA 26A; MICRORNA 299; MICRORNA 29B; MICRORNA 31; MICRORNA 339; MICRORNA 33B; MICRORNA 363; MICRORNA 365A; MICRORNA 365B; MICRORNA 378A; MICRORNA 425; MICRORNA 550A; MICRORNA 552; MICRORNA 589; MICRORNA 592; MICRORNA 7; MICRORNA 94; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; NEXT GENERATION SEQUENCING; NOMOGRAM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; COLON TUMOR; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL;

AGED; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NOMOGRAMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84921060390     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0544-T     Document Type: Article

References (50)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Moss EG. MicroRNAs: hidden in the genome. Curr Biol 2002;12:R138-R140.
3. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch 2008;452:1-10.
4. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
5. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
6. McManus MT.MicroRNAs and cancer. Semin Cancer Biol 2003;13:253-8.
7. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122:6-7.
8. Ma L, Weinberg RA. MicroRNAs in malignant progression. Cell Cycle 2008;7:570-2.
9. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22: 3408-19.
10. Nitsche U, Maak M, Schuster T, Kunzli B, Langer R, Slotta-Huspenina J, et al. Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective. Ann Surg 2011;254:793-800.
11. Quirke P, Cuvelier C, Ensari A, Glimelius B, Laurberg S, Ortiz H, et al. Evidence-based medicine: the time has come to set standards for staging. J Pathol 2010;221:357-60.
12. van Cutsem E, Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2009;20 Suppl 4:49-50.
13. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9:293-302.
14. de Krijger I, Mekenkamp LJ, Punt CJ, Nagtegaal ID. MicroRNAs in colorectal cancer metastasis. J Pathol 2011;224:438-47.
15. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
16. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 2006;103:2746-51.
17. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009;55:623-31.
18. Lechpammer M, Sgroi DC. Laser Capture Microdissection: a rising tool in genetic profiling of cancer. Expert Rev Mol Diagn 2004;4:429-30.
19. 't Hoen PA, Ariyurek Y, Thygesen HH, Vreugdenhil E, Vossen RH, de Menezes RX, et al. Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. Nucleic Acids Res 2008;36:e141.
20. Lin M, Chen W, Huang J, Gao H, Ye Y, Song Z, et al. MicroRNA expression profiles in human colorectal cancers with liver metastases. Oncol Rep 2011;25:739-47.
21. Rohr C, Kerick M, Fischer A, Kuhn A, Kashofer K, Timmermann B, et al. High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS ONE 2013;8:e67461.
22. Schee K, Lorenz S, Worren MM, Gunther CC, Holden M, Hovig E, et al. Deep sequencing the MicroRNA transcriptome in colorectal cancer. PLoS ONE 2013;8:e66165.
23. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008;68:6416-24.
24. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 2013;14:1295-306.
25. Maak M, Simon I, Nitsche U, Roepman P, Snel M, Glas AM, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 2013;257:1053-8.
26. Zeestraten EC, Reimers MS, Saadatmand S, Dekker JW, Liefers GJ, van den Elsen PJ, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer 2014;110:459-68.
27. Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, et al. Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer 2012;106:133-40.
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91.
29. Buermans HP, Ariyurek Y, van OG, den Dunnen JT, 't Hoen PA. New methods for next generation sequencing based microRNA expression profiling. BMC Genomics 2010;11:716.
30. Nolte-'t Hoen EN, Buermans HP, Waasdorp M, Stoorvogel W, Wauben MH, 't Hoen PA. Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res 2012; 40:9272-85.
31. de Hoon MJ, Taft RJ, Hashimoto T, Kanamori-Katayama M, Kawaji H, Kawano M, et al. Cross-mapping and the identification of editing sites in mature microRNAs in high-throughput sequencing libraries. Genome Res 2010;20:257-64.
32. Garmire LX, Subramaniam S. Evaluation of normalization methods in mammalian microRNA-Seq data. RNA 2012;18:1279-88.
33. Garmire LX, Subramaniam S. The poor performance of TMM on micro-RNA-Seq. RNA 2013;19:735-6.
34. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007;26:2389-430.
35. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
36. Huijbers A, Tollenaar RA, Pelt GW, Zeestraten EC, Dutton S, McConkey CC, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013;24:179-85.
37. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
38. Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF, et al. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol 2009;33:572-82.
39. Kjaer-Frifeldt S, Hansen TF, Nielsen BS, Joergensen S, Lindebjerg J, Soerensen FB, et al. The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer 2012;107:1169-74.
40. Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, Hansen U, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011;28:27-38.
41. Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, et al. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011;10:340-7.
42. Caruso S, Bazan V, Rolfo C, Insalaco L, Fanale D, BronteG, et al. MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? Oncogenesis 2012;1:e32.
43. Kurokawa K, Tanahashi T, Iima T, Yamamoto Y, Akaike Y, Nishida K, et al. Role ofmiR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol 2012;47:883-95.
44. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 2010;10:173.
45. Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett 2013;335:168-74.
46. Nishida N, Nagahara M, Sato T, Mimori K, Sudo T, Tanaka F, et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res 2012;18: 3054-70.
47. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of themiR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010;3:ra29.
48. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-21.
49. Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, et al. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer 2010; 10:542.
50. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, et al. MicroRNAs associated with metastatic prostate cancer. PLoS ONE 2011;6: e24950.